Clinically relevant benefit of mepolizumab and benralizumab in asthma following EGPA in real-life settings
C. Desaintjean (Lyon, France), M. Nasser (Lyon, France), K. Ahmad (Lyon, France), J. Traclet (Lyon, France), S. Turquier (Lyon, France), J. Glérant (Lyon, France), V. Cottin (Lyon, France)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2132
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Desaintjean (Lyon, France), M. Nasser (Lyon, France), K. Ahmad (Lyon, France), J. Traclet (Lyon, France), S. Turquier (Lyon, France), J. Glérant (Lyon, France), V. Cottin (Lyon, France). Clinically relevant benefit of mepolizumab and benralizumab in asthma following EGPA in real-life settings. 2132
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|